50 years dedicated to excellence in nuclear medicine
The IRE or the National Institute for Radioelements is a public utility foundation, whose main activity is the production of radioisotopes for diagnostic and therapeutic applications in the field of nuclear medicine. The IRE is the world leader in the production of molybdenum-99, the "parent" isotope of metastable technetium-99, and the most widely used in nuclear medicine for many examinations (heart, bone, lungs, thyroid, brain, kidneys, etc).
In addition to its production activities, the IRE contributes to protection and environmental monitoring through its services of measuring radioactivity in various samples, radiological characterisation of waste and contaminated elements and consultancy and technical assistance in the fields of radiology and nuclear energy.
For its part, IRE ELiT is IRE's innovation subsidiary founded in 2010 to develop radiopharmaceuticals used for imaging and treatment of certain cancers and palliative care. In 2020, the group devoted 15% of its turnover to R&D, a percentage which has been steadily increasing since the company's creation. IRE and IRE ELiT currently employ 250 people.
